OMAPATRILAT
| Title | Journal |
|---|---|
| Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. | Naunyn-Schmiedeberg's archives of pharmacology 20121101 |
| Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. | Journal of cardiovascular pharmacology 20110401 |
| Combined neutral endopeptidase inhibitors. | Expert opinion on investigational drugs 20110401 |
| Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. | Journal of medicinal chemistry 20100114 |
| Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. | American journal of physiology. Gastrointestinal and liver physiology 20090701 |
| Endothelium-dependent relaxation factor released by perivascular adipose tissue. | Journal of hypertension 20090401 |
| Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction. | Molecular and cellular biochemistry 20090101 |
| The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment. | Folia medica Cracoviensia 20090101 |
| Synthesis and antihypertensive effects of new methylthiomorpholinphenol derivatives. | European journal of medicinal chemistry 20080301 |
| Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. | British journal of pharmacology 20080301 |
| Omapatrilat enhances adrenomedullin's reduction of cardiomyocyte cell death. | European journal of pharmacology 20070521 |
| Chronic effect of combined treatment with omapatrilat and adrenomedullin on the progression of heart failure in rats. | American journal of hypertension 20061001 |
| Enhancement of muscle glucose uptake by the vasopeptidase inhibitor, omapatrilat, is independent of insulin signaling and the AMP kinase pathway. | The Journal of endocrinology 20060801 |
| Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat. | Clinical and experimental hypertension (New York, N.Y. : 1993) 20060701 |
| Bioenergetic protection of failing atrial and ventricular myocardium by vasopeptidase inhibitor omapatrilat. | American journal of physiology. Heart and circulatory physiology 20060401 |
| Study of bradykinin metabolism by rat lung tissue membranes and rat kidney brush border membranes by HPLC with inductively coupled plasma-mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. | Journal of peptide science : an official publication of the European Peptide Society 20060301 |
| Evaluation of the enhanced oral effect of omapatrilat-monolein nanoparticles prepared by the emulsification-diffusion method. | Journal of nanoscience and nanotechnology 20060101 |
| Pharmacological enhancement of the kallikrein-kinin system promotes anti-fibrotic responses in human mesangial cells. | Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20060101 |
| Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. | The Journal of pharmacology and experimental therapeutics 20051201 |
| Renoprotective effect of long-term combined treatment with adrenomedullin and omapatrilat in hypertensive rats. | Journal of hypertension 20051201 |
| Effect of omapatrilat on the aging process of the normal rat. | Cellular and molecular biology (Noisy-le-Grand, France) 20051108 |
| Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. | Journal of hypertension 20051101 |
| Changes in aortic stiffness and augmentation index after acute converting enzyme or vasopeptidase inhibition. | Hypertension (Dallas, Tex. : 1979) 20051101 |
| Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies. | American journal of physiology. Renal physiology 20051001 |
| Vasopeptidase inhibition peri- and post-MI in Zucker insulin resistant rats: effect on MI size, arrhythmias, remodeling, function and fetal gene expression. | Cardiovascular drugs and therapy 20051001 |
| Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. | European journal of pharmacology 20050920 |
| Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats. | Journal of hypertension 20050901 |
| Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure. | Heart rhythm 20050901 |
| The kallikrein-kinin system: current and future pharmacological targets. | Journal of pharmacological sciences 20050901 |
| Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy? | Journal of hypertension 20050801 |
| Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. | American heart journal 20050801 |
| Effects of vasopeptidase inhibition on renal function and tubuloglomerular feedback in spontaneously hypertensive rats. | Hypertension research : official journal of the Japanese Society of Hypertension 20050701 |
| Predicting drug metabolism--an evaluation of the expert system METEOR. | Chemistry & biodiversity 20050701 |
| Effects of the vasopeptidase inhibitor omapatrilat on peri- and postmyocardial infarction in Zucker lean rats. | The Canadian journal of cardiology 20050301 |
| The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule. | Journal of hypertension 20050201 |
| Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. | Journal of hypertension 20050201 |
| The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides. | Canadian journal of physiology and pharmacology 20050201 |
| Changes in production and metabolism of brain natriuretic peptide in rats with myocardial necrosis. | European journal of pharmacology 20050110 |
| Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats. | Bratislavske lekarske listy 20050101 |
| Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet. | Hypertension research : official journal of the Japanese Society of Hypertension 20040801 |
| [OCTAVE and OPERA: discordance in hypertension therapy?]. | Herz 20040501 |
| Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension. | European journal of pharmacology 20040206 |
| Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. | American journal of hypertension 20040201 |
| Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. | Journal of cardiac failure 20040201 |
| Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. | Journal of hypertension 20040201 |
| Systemic and renal effect of chronic omapatrilat in sodium-restricted, one-kidney, one-clip hypertensive rats. | Journal of hypertension 20040201 |
| Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice. | Journal of cardiovascular pharmacology 20040101 |
| Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats. | Clinical and experimental hypertension (New York, N.Y. : 1993) 20040101 |
| Role of Angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling. | Journal of vascular research 20040101 |
| [The new class of drugs-- metalloprotease inhibitors -- in the treatment of heart failure]. | Klinicheskaia meditsina 20040101 |
| Trial logistics, implementation, and conduct of the OCTAVE mega study in Germany. Prospective, randomised, double-blind study to compare the efficacy and tolerability of omapatrilat and enalapril. | Arzneimittel-Forschung 20040101 |
| Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure. | Molecular and cellular biochemistry 20031201 |
| Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats. | Vascular pharmacology 20031201 |
| Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats. | Hypertension (Dallas, Tex. : 1979) 20031101 |
| Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats. | American journal of hypertension 20031101 |
| Role of systolic blood pressureon the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats). | American journal of hypertension 20031101 |
| Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects. | British journal of clinical pharmacology 20031001 |
| Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20031001 |
| Regression of left ventricular hypertrophy is a key goal of hypertension management. | Current hypertension reports 20030801 |
| Recent clinical trials with omapatrilat: new developments. | Current hypertension reports 20030801 |
| Omapatrilat induces profound renal vasodilation but does not affect coronary hemodynamics. | Journal of cardiovascular pharmacology and therapeutics 20030601 |
| Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. | Circulation 20030415 |
| Comparative biotransformation of radiolabeled [(14)C]omapatrilat and stable-labeled [(13)C(2)]omapatrilat after oral administration to rats, dogs, and humans. | Drug metabolism and disposition: the biological fate of chemicals 20030101 |
| Quantitative determination of omapatrilat and its metabolites in human plasma by HPLC coupled with tandem mass spectrometry. | Acta pharmacologica Sinica 20030101 |
| Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats. | American journal of hypertension 20030101 |
| Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension. | Journal of hypertension 20030101 |
| [The best of cardiac failure in 2002]. | Archives des maladies du coeur et des vaisseaux 20030101 |
| Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice. | International journal of experimental diabesity research 20030101 |
| Renoprotective effects of omapatrilat are mediated partially by bradykinin. | American journal of nephrology 20030101 |
| [From basic research to clinical results. The OVERTURE, ENABLE, and RENEWAL studies]. | Archivos de cardiologia de Mexico 20030101 |
| Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20021201 |
| Omapatrilat--the story of Overture and Octave. | International journal of cardiology 20021101 |
| Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake. | Journal of the American Society of Nephrology : JASN 20021001 |
| Homocysteine and vascular disease. | European heart journal 20021001 |
| Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension. | Hypertension (Dallas, Tex. : 1979) 20021001 |
| Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. | European heart journal 20021001 |
| Recent clinical trial updates. | Circulation 20020917 |
| Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. | The American journal of cardiology 20020901 |
| Vasopeptidase inhibitors in heart failure. | Journal of the renin-angiotensin-aldosterone system : JRAAS 20020901 |
| Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). | Circulation 20020820 |
| Vasopeptidase inhibition in a canine model of exercise-induced left ventricular dysfunction. | Clinical and experimental pharmacology & physiology 20020801 |
| Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session. | Journal of the American College of Cardiology 20020703 |
| Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. | Circulation 20020625 |
| Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. | American journal of hypertension 20020601 |
| Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure. | American heart journal 20020601 |
| Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? | Journal of cardiac failure 20020601 |
| Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. | Journal of hypertension 20020501 |
| Promises kept and broken: new pharmaceuticals. | The Canadian journal of cardiology 20020501 |
| Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. | Circulation 20020205 |
| Neprilysin inhibitors potentiate effects of bradykinin on b2 receptor. | Hypertension (Dallas, Tex. : 1979) 20020201 |
| [Heart failure and vasopeptidase inhibitors]. | Archives des maladies du coeur et des vaisseaux 20020201 |
| A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure. | Pharmacotherapy 20020101 |
| The cardiovascular actions of omapatrilat in spontaneously hypertensive rats. | Current hypertension reports 20011201 |
| Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. | Hypertension (Dallas, Tex. : 1979) 20011201 |
| Pharmacodynamics and pharmacokinetics of omapatrilat in heart failure. | Journal of clinical pharmacology 20011201 |
| Omapatrilat: neurohormonal and pharmacodynamic profile when administered with furosemide. | Journal of clinical pharmacology 20011201 |
| LC/MS/MS determination of omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor, and its sulfhydryl- and thioether-containing metabolites in human plasma. | Analytical chemistry 20011115 |
| Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. | Journal of the American Society of Nephrology : JASN 20011001 |
| Omapatrilat. Bristol-Myers Squibb. | Current opinion in investigational drugs (London, England : 2000) 20011001 |
| Effects of omapatrilat on hemodynamics and safety in patients with heart failure. | The American journal of cardiology 20010915 |
| Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. | Kidney international 20010801 |
| Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone. | American journal of hypertension 20010801 |
| Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. | Hypertension (Dallas, Tex. : 1979) 20010801 |
| Enzymatic synthesis of chiral intermediates for Omapatrilat, an antihypertensive drug. | Biomolecular engineering 20010601 |
| Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction. | Peptides 20010601 |
| Update in pharmacologic treatment of hypertension. | Cardiology clinics 20010501 |
| Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. | Atherosclerosis 20010401 |
| Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. | Journal of cardiovascular pharmacology 20010401 |
| Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. | Hypertension (Dallas, Tex. : 1979) 20010401 |
| Angioedema and antihypertensive therapy. | Wiener klinische Wochenschrift 20010315 |
| Metabolism of [(14)C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans. | Drug metabolism and disposition: the biological fate of chemicals 20010101 |
| [Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure]. | Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20010101 |
| Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with omapatrilat, a vasopeptidase inhibitor. | Journal of clinical hypertension (Greenwich, Conn.) 20010101 |
| Omapatrilat normalizes renal function curve in spontaneously hypertensive rats. | BMC pharmacology 20010101 |
| Effects of omapatrilat on blood pressure and insulin sensitivity in an animal model of insulin resistance. | Blood pressure 20010101 |